Comparing Biosig Technologies (NASDAQ:STEX) and TranS1 (OTCMKTS:BAXSQ)

TranS1 (OTCMKTS:BAXSQ) and Biosig Technologies (NASDAQ:STEX) are both manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for TranS1 and Biosig Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TranS1	0	0	0	0	0.00
Biosig Technologies	1	0	1	0	2.00

Biosig Technologies has a consensus target price of $9.00, suggesting a potential upside of 902.90%. Given Biosig Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe Biosig Technologies is more favorable than TranS1.

Valuation & Earnings

This table compares TranS1 and Biosig Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TranS1	N/A	N/A	N/A	N/A	N/A
Biosig Technologies	$40,000.00	4,063.88	-$462.77 million	($9.58)	-0.09

TranS1 has higher earnings, but lower revenue than Biosig Technologies.

Profitability

This table compares TranS1 and Biosig Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TranS1	N/A	N/A	N/A
Biosig Technologies	N/A	-1,476.78%	-428.30%

Institutional & Insider Ownership

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biosig Technologies beats TranS1 on 6 of the 8 factors compared between the two stocks.

About TranS1

Baxano Surgical, Inc., formerly Baxano Inc. is a medical device company. The Company is focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. The Company markets the AxiaLIF pre-sacral access and interbody fusion system for single and two level lower lumbar fusion, the VEO lateral access and interbody fusion system, the iO-Flex set of flexible instruments used by surgeons during spinal decompression procedures, and the iO-Tome instrument for rapid and precise removal of bone, specifically the facet joints, a technique which is commonly performed in spinal fusion procedures. The Company’s other products include: Vectre facet screw system, Bi-Ostetic bone void filler, bowel retractors, discectomy tools, and a bone graft harvesting system that can be used to extract bone graft from the patient’s hip for use in fusion procedures.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.